A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia – Beigene

⟵ Back to Search Results

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Beigene Study ID

BGB-3111-305

ClinicalTrials.gov ID

NCT03734016

EudraCT Number

2018-001366-42

China Drug Trials ID

CTR20190098

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents